Spitäler Schaffhausen and Hirslanden cooperate in Urology
10.09.2020 | PDF | 183.76 KB
The Centre for Urology Zurich at Klinik Hirslanden and Spitäler Schaffhausen are set to work together within the medical specialty of urology in the future. The declared goal is to ensure the fulfilment of cantonal performance mandates including highly specialised medicine interventions in the Schaffhausen care region, and thus optimal care for patients.
In the future, Schaffhausen patients who have to undergo complex urological procedures in the field of highly specialised medicine (HSM) will be treated at Kantonsspital Schaffhausen and at Klinik Hirslanden in Zurich. During the treatment of these patients, the procedure is carried out jointly at Klinik Hirslanden in Zurich, and the preliminary and follow-up care at Kantonsspital Schaffhausen. "Our patients in the region benefit from this cooperation by receiving the entire range of urological procedures, including highly specialised medicine, from a single source," says Arend Wilpshaar, Chairman of the Hospital Management at Spitäler Schaffhausen. As part of the cooperation, Dr. med. Stefan Preusser, a senior consultant at the Urology Clinic at Kantonsspital Schaffhausen, will be accredited to Klinik Hirslanden in order to operate on Schaffhausen patients with a complex clinical picture in Zurich.
The cooperation will also strengthen robotics in the field of urology at Kantonsspital Schaffhausen. For this purpose, PD Dr. med. Niko Zantl from the Centre for Urology Zurich will be accredited as an affiliated doctor at Kantonsspital Schaffhausen and will offer consultations at the practice "Centre for Urology Schaffhausen". The cooperation between Kantonsspital Schaffhausen and the "Centre for Urology Schaffhausen", in particular Dr. med. Markus Schönberger, who works as an affiliated doctor at the Kantonsspital, has been successfully underway since the end of 2018.
The aim of the two cooperation partners is to jointly increase quality and competitiveness. In addition, they will support each other with regard to postgraduate medical training in the field of urology.
Klinik Hirslanden is a European cancer centre certified by the German Cancer Society (DKG) and runs a certified prostate cancer centre as well as a uro-oncology centre for bladder, kidney, testicle and penis cancer under the umbrella of the European cancer centre. The Centre for Urology Zurich (ZfU) is one of the partners of the certified prostate cancer and uro-oncology centre. The ZfU offers the entire spectrum of outpatient and inpatient urological diagnostics and treatments. All urological operations are performed in line with the latest scientific and technical standards. "The ZfU fulfils all of the prerequisites for carrying out complex urological procedures in the field of highly specialised medicine, which Schaffhausen patients will benefit from in the future," says Dr. Stephan Pahls, Chief Operating Officer East of the Hirslanden Group.
The Hirslanden Group operates 17 hospitals in 10 cantons, many of which have an emergency department. It also operates 4 outpatient surgical units, 17 radiology institutes and 5 radiotherapy institutes. Together with public and private cooperation partners, Hirslanden focuses on the continuum of care, promoting high-quality, responsible, personalised and efficiently integrated healthcare. The Group has 2,506 affiliated doctors and 10,417 employees, of whom 498 are permanently employed doctors. Hirslanden is the largest medical network in Switzerland. In the 2019/20 financial year, the Group generated turnover of CHF 1,804 million. As at 31.3.2020, the Group had treated 107,491 patients, amounting to a total of 471,717 inpatient days. In insurance terms, the patient mix consists of 49.2% basic, 29.3% semi-private, and 21.5% private insured patients.
Hirslanden is synonymous with first-class medical care provided by highly qualified medical specialists with many years of experience. As a system provider, the Group stands out from the rest of the market: interdisciplinary medical centres of expertise and specialised institutes enable it to offer the best possible individualised treatment, even in highly complex cases. The Hirslanden Group was formed in 1990 through the merger of several hospitals. Since 2007 it has been part of the international hospital group Mediclinic International plc, which is listed on the London Stock Exchange.